ArticleAmerican journal of translational research2026
Complete revascularization improves blood pressure control and clinical prognosis in patients with acute myocardial infarction by reducing oxidative stress.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the effects of complete revascularization on oxidative stress, blood pressure control, and prognosis in patients with acute myocardial infarction (AMI).
methodsClinical data from 80 AMI patients were retrospectively analyzed. Based on the SYNTAX Revascularization Index (SRI), patients were classified into the complete revascularization group (SRI=100%, n=31), partial revascularization group (SRI 50-99%, n=27), and low revascularization group (SRI<50%, n=22). Postoperative oxidative stress markers (malondialdehyde, MDA; angiotensin converting enzyme, ACE; and superoxide dismutase, SOD), myocardial injury marker (cardiac Troponin I, cTnI), and ambulatory blood pressure parameters were compared among groups. Their correlations were analyzed, and the predictive value of SRI for major adverse cardiovascular events (MACE) was evaluated.
resultsOne month after surgery, the complete revascularization group exhibited significantly lower MDA than the partial and low revascularization groups, higher SOD, and lower ACE and cTnI levels (all P<0.001). Six months postoperatively, the complete revascularization group showed improvements in 24 h SBP, 24 h SBP-SD and nocturnal blood pressure decline rate (all P<0.01). The incidence of MACE was significantly lower in the complete revascularization group (6.45% vs. 36.73%, P=0.002). Logistic regression showed that SRI was an independent protective factor for MACE (OR=0.119, 95% CI: 0.025-0.557, P=0.007). ROC curve analysis indicated its predictive value for MACE with an AUC of 0.835 and an optimal cut-off value of 69.360%.
conclusionComplete revascularization improves blood pressure stability and reduces MACE risk in AMI patients by alleviating oxidative stress. Achieving an SRI above 69.360% can be considered a clinical target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.